<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754546</url>
  </required_header>
  <id_info>
    <org_study_id>21261</org_study_id>
    <nct_id>NCT00754546</nct_id>
  </id_info>
  <brief_title>Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD</brief_title>
  <acronym>ARFEET</acronym>
  <official_title>Effects of Arformoterol on Exercise Endurance Time and Breathlessness in COPD: Cycle Ergometer vs. Treadmill</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies suggest that treadmill exercise may be a more relevant exercise stimulus
      than the cycle ergometer to demonstrate benefits with bronchodilator therapy in patients with
      COPD. The hypothesis of the study is that patients with COPD will exhibit greater
      improvements in exercise endurance and breathlessness with arformoterol compared with normal
      saline during treadmill walking than with cycle exercise.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized trial with crossover of consecutively recruited patients with
      symptomatic COPD. Each patient will participate in seven visits over a 3-4 week period. At
      the first visit patients will provide informed consent and then be familiarized with
      equipment and testing protocols. At visits 2 and 3 patients will inhale 2 puffs of albuterol
      HFA MDI, and then perform symptom limited incremental exercise on the treadmill or cycle
      ergometer (randomized order); after a one hour rest, the patient will perform constant work
      exercise at 80-85% of peak VO2 on the same exercise mode.

      At visits 4 - 7, patients will perform PFTs at baseline and at 30 and 120 minutes after
      inhaling arformoterol or normal saline (randomized order) and then constant work exercise on
      the treadmill or cycle ergometer (randomized order). Metabolic measurements will be made
      throughout exercise, and patients will provide continuous ratings of breathlessness and leg
      discomfort using a system consisting of a computer, monitor, and a mouse.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise Endurance Time</measure>
    <time_frame>After one dose</time_frame>
    <description>Participants were asked to exercise until symptom limitation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Linear Regression Between Breathlessness Ratings (on 0 - 10 Borg Scale) and Time Throughout Exercise</measure>
    <time_frame>After one dose</time_frame>
    <description>linear regression slope of breathlessness - time for arformoterol and for normal saline will be compared between treadmill and cycle exercise
The higher the number the worse the shortness of breath</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Arformoterol tartrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bronchodilator therapy with arformoterol solution 15 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo using normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arformoterol tartrate</intervention_name>
    <description>15 mcg in two ml solution administered via nebulizer</description>
    <arm_group_label>Arformoterol tartrate</arm_group_label>
    <other_name>Brovana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo: Normal Saline</intervention_name>
    <description>Normal saline was nebulized.</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treadmill Exercise</intervention_name>
    <arm_group_label>Arformoterol tartrate</arm_group_label>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cycle Exercise</intervention_name>
    <arm_group_label>Arformoterol tartrate</arm_group_label>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female patient 50 years of age or older; diagnosis of COPD; current or
             ex-smoker with at least 10 pack-years of smoking; a patient-reported score for
             breathlessness during activities of daily living of &lt; 9 on the self-administered
             computerized baseline dyspnea index; a post-bronchodilator FEV1 &lt; 80% predicted; a
             post-bronchodilator FEV1/FVC ratio &lt; 70%; and clinically stable condition.

        Exclusion Criteria:

          -  any concomitant disease that interferes with study procedures or evaluation; inability
             to exercise on the treadmill or cycle ergometer; inability to withhold short-acting
             bronchodilators for 4 hours or long-acting bronchodilators for 12 hrs (salmeterol or
             formoterol) and for 24 hours (tiotropium) prior to testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doanld A Mahler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Zhang X, Waterman LA, Ward J, Baird JC, Mahler DA. Advantages of endurance treadmill walking compared with cycling to assess bronchodilator therapy. Chest. 2010 Jun;137(6):1354-61. doi: 10.1378/chest.09-2470. Epub 2009 Dec 29.</citation>
    <PMID>20040610</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <results_first_submitted>August 3, 2009</results_first_submitted>
  <results_first_submitted_qc>May 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2013</results_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exercise;</keyword>
  <keyword>treadmill;</keyword>
  <keyword>cycle ergometer;</keyword>
  <keyword>breathlessness;</keyword>
  <keyword>leg discomfort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from a specialty clinic in Lebanon, NH, between August 1, 2008 to May 1, 2009.</recruitment_details>
      <pre_assignment_details>27 particpants recruited; 27 particpants screened; 5 excluded because they did not meet inclusion criteria; 2 patients withdrew consent after visit 1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>All 20 participants were randomized to receive all 4 of the interventions in a randomzied sequence. The 4 interventions follow:
Treadmill exercise-Arformoterol Treadmill exercise-Normal Saline Cycle exercise-Arformoterol Cycle exercise-Normal Saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All 20 participants were randomized to receive all 4 of the interventions in a randomzied sequence. The 4 interventions follow:
Treadmill exercise-Arformoterol Treadmill exercise-Normal Saline Cycle exercise-Arformoterol Cycle exercise-Normal Saline</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exercise Endurance Time</title>
        <description>Participants were asked to exercise until symptom limitation</description>
        <time_frame>After one dose</time_frame>
        <population>Number of participants determined by previous studies. Analysis was intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treadmill Exercise With the Active Comparator</title>
          </group>
          <group group_id="O2">
            <title>Cycle Exercise With the Active Comparator</title>
          </group>
          <group group_id="O3">
            <title>Treadmill Exercise With the Placebo Comparator</title>
          </group>
          <group group_id="O4">
            <title>Cycle Exercise With the Placebo Comparator</title>
          </group>
        </group_list>
        <measure>
          <title>Exercise Endurance Time</title>
          <description>Participants were asked to exercise until symptom limitation</description>
          <population>Number of participants determined by previous studies. Analysis was intention to treat</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490" spread="258"/>
                    <measurement group_id="O2" value="333" spread="158"/>
                    <measurement group_id="O3" value="472" spread="258"/>
                    <measurement group_id="O4" value="362" spread="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA was used to examine the interaction between mode of exercise and treatment effect.
Twenty patients were considered adequate to provide a power of 85% with an alpha of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparing arformoterol with placebo with treadmill exercise</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Arformoterol versus normal saline with cycle exercise</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Linear Regression Between Breathlessness Ratings (on 0 - 10 Borg Scale) and Time Throughout Exercise</title>
        <description>linear regression slope of breathlessness - time for arformoterol and for normal saline will be compared between treadmill and cycle exercise
The higher the number the worse the shortness of breath</description>
        <time_frame>After one dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treadmill Exercise With the Active Comparator</title>
          </group>
          <group group_id="O2">
            <title>Cycle Exercise With the Active Comparator</title>
          </group>
          <group group_id="O3">
            <title>Treadmill Exercise With the Placebo Comparator</title>
          </group>
          <group group_id="O4">
            <title>Cycle Exercise With the Placebo Comparator</title>
          </group>
        </group_list>
        <measure>
          <title>Linear Regression Between Breathlessness Ratings (on 0 - 10 Borg Scale) and Time Throughout Exercise</title>
          <description>linear regression slope of breathlessness - time for arformoterol and for normal saline will be compared between treadmill and cycle exercise
The higher the number the worse the shortness of breath</description>
          <units>breathlessness units/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.56"/>
                    <measurement group_id="O2" value="1.79" spread="1.05"/>
                    <measurement group_id="O3" value="1.42" spread="0.97"/>
                    <measurement group_id="O4" value="1.49" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treadmill Exercise With the Active Comparator</title>
        </group>
        <group group_id="E2">
          <title>Cycle Exercise With the Active Comparator</title>
        </group>
        <group group_id="E3">
          <title>Treadmill Exercise With the Placebo Comparator</title>
        </group>
        <group group_id="E4">
          <title>Cycle Exercise With the Placebo Comparator</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study completed with no reported adverse effects. One limitation of the study is frequent exercise tests involving 7 visits for each participant</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Donald A. Mahler, M.D.</name_or_title>
      <organization>Dartmouth-Hitchcock Medical Center</organization>
      <phone>603 650-5533</phone>
      <email>Donald.a.mahler@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

